

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

- 1.-62. (Canceled).
63. (New) An antibody or fragment thereof that binds to human mannose binding lectin (MBL), comprising:
a CDR3 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.
64. (New) The antibody or fragment thereof of claim 63, wherein the CDR3 is a heavy chain CDR3.
65. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof comprises a CDR3 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.
66. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof comprises a CDR3 of a monoclonal antibody produced by hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.
67. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof comprises a CDR3 of a monoclonal antibody produced by hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

68. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof is a monoclonal antibody.

69. (New) The antibody or fragment thereof of claim 68, wherein the monoclonal antibody is produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

70. (New) The antibody or fragment thereof of claim 68, wherein the monoclonal antibody is produced by hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

71. (New) The antibody or fragment thereof of claim 68, wherein the monoclonal antibody is produced by hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

72. (New) The antibody or fragment thereof of claim 68, wherein the monoclonal antibody is a humanized monoclonal antibody.

73. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof is a single chain antibody.

74. (New) The antibody or fragment thereof of claim 63, wherein the antibody or fragment thereof is an $F(ab')_2$ fragment, an Fab fragment, an Fv fragment, or an Fd fragment.

75. (New) The antibody or fragment thereof of claim 63, further comprising:
a CDR2 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

76. (New) The antibody or fragment thereof of claim 75, wherein the CDR2 is a light chain CDR2.

77. (New) The antibody or fragment thereof of claim 63, further comprising:
a CDR1 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

78. (New) The antibody or fragment thereof of claim 77, wherein the CDR1 is a light chain CDR1.

79. (New) The antibody or fragment thereof of claim 77, further comprising:
a CDR2 of a monoclonal antibody produced by hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621, hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620, or hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

80. (New) A hybridoma cell line 3F8 deposited under ATCC Accession No. HB-12621.

81. (New) A hybridoma cell line 2A9 deposited under ATCC Accession No. HB-12620.

82. (New) A hybridoma cell line hMBL1.2 deposited under ATCC Accession No. HB-12619.

83. (New) A composition comprising:
the antibody or fragment thereof of claim 63 and a pharmaceutically acceptable carrier.

84. (New) The composition of claim 83, wherein the antibody or fragment thereof is in an amount effective to treat an MBL mediated disorder.

Serial No.: 09/464,303
Conf. No.: 7348

- 5 -

Art Unit: 1644

85. (New) The composition of claim 83, further comprising a drug for the treatment of an MBL mediated disorder.